Literature DB >> 16357140

Gene expression profiles associated with treatment response in oligodendrogliomas.

Pim J French1, Sigrid M A Swagemakers, Jord H A Nagel, Mathilde C M Kouwenhoven, Eric Brouwer, Peter van der Spek, Theo M Luider, Johan M Kros, Martin J van den Bent, Peter A Sillevis Smitt.   

Abstract

Oligodendrogliomas are a specific subtype of brain tumor of which the majority responds favorably to chemotherapy. In this study, we made use of expression profiling to identify chemosensitive oligodendroglial tumors. Correlation of expression profiles to loss of heterozygosity on 1p and 19q, common chromosomal aberrations associated with response to treatment, identified 376, 64, and 60 differentially expressed probe sets associated with loss of 1p, 19q or 1p, and 19q, respectively. Correlation of expression profiles to the tumors' response to treatment identified 16 differentially expressed probe sets. Because transcripts associated with chemotherapeutic response were identified independent of common chromosomal aberrations, expression profiling may be used as an alternative approach to the tumors' 1p status to identify chemosensitive oligodendroglial tumors. Finally, we correlated expression profiles to survival of the patient after diagnosis and identified 103 differentially expressed probe sets. The observation that many genes are differentially expressed between long and short survivors indicates that the genetic background of the tumor is an important factor in determining the prognosis of the patient. Furthermore, these transcripts can help identify patient subgroups that are associated with favorable prognosis. Our study is the first to correlate gene expression with chromosomal aberrations and clinical performance (response to treatment and survival) in oligodendrogliomas. The differentially expressed transcripts can help identify patient subgroups with good prognosis and those that will benefit from chemotherapeutic treatments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357140     DOI: 10.1158/0008-5472.CAN-05-1886

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.

Authors:  Lina Y Dimberg; Christina G Towers; Kian Behbakht; Taylor J Hotz; Jihye Kim; Susan Fosmire; Christopher C Porter; Aik-Choon Tan; Andrew Thorburn; Heide L Ford
Journal:  Mol Cancer Res       Date:  2017-01-20       Impact factor: 5.852

2.  Elevated HMGN4 expression potentiates thyroid tumorigenesis.

Authors:  Jamie Kugler; Yuri V Postnikov; Takashi Furusawa; Shioko Kimura; Michael Bustin
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

3.  IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance.

Authors:  Colin D White; Zhigang Li; Deborah A Dillon; David B Sacks
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

Review 4.  Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate.

Authors:  Steven D Rosen; Hassan Lemjabbar-Alaoui
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

5.  Overexpression and biological function of IQGAP3 in human pancreatic cancer.

Authors:  Weihong Xu; Bin Xu; Yiting Yao; Xiaoling Yu; Hua Cao; Jun Zhang; Jie Liu; Huiming Sheng
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

6.  Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.

Authors:  Walter Taal; Carin C D van der Rijt; Winand N M Dinjens; Peter A E Sillevis Smitt; Agnes A A C M Wertenbroek; Jacoline E C Bromberg; Irene van Heuvel; Johan M Kros; Martin J van den Bent
Journal:  J Neurooncol       Date:  2014-10-26       Impact factor: 4.130

7.  ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.

Authors:  Cody L Nesvick; Chao Zhang; Nancy A Edwards; Blake K Montgomery; Michaela Lee; Chunzhang Yang; Herui Wang; Dongwang Zhu; John D Heiss; Marsha J Merrill; Abhik Ray-Chaudhury; Zhengping Zhuang
Journal:  J Neurooncol       Date:  2016-08-27       Impact factor: 4.130

8.  An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.

Authors:  François Ducray; Aurélien de Reyniès; Olivier Chinot; Ahmed Idbaih; Dominique Figarella-Branger; Carole Colin; Lucie Karayan-Tapon; Hervé Chneiweiss; Michel Wager; François Vallette; Yannick Marie; David Rickman; Emilie Thomas; Jean-Yves Delattre; Jérôme Honnorat; Marc Sanson; François Berger
Journal:  Mol Cancer       Date:  2010-09-07       Impact factor: 27.401

Review 9.  Targeting SphK1 as a new strategy against cancer.

Authors:  Dai Shida; Kazuaki Takabe; Dmitri Kapitonov; Sheldon Milstien; Sarah Spiegel
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

Review 10.  Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex.

Authors:  J Moscat; M T Diaz-Meco; M W Wooten
Journal:  Cell Death Differ       Date:  2009-08-28       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.